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Background: Early diagnosis of HCV infection is based on detection of antibodies against HCV proteins
using recombinant viral antigens. The present study was designed to select, clone and express the
antigenic regions of Core and E2 genes from local HCV-3a genotype and to utilize the antigenic
recombinant proteins (Core & E2) to develop highly sensitive, speciﬁc and economical diagnostic assays
for detection of HCV infection.
Methods: The antigenic sites were determined within Core and E2 genes and were then cloned in pET-
28a expression vector. The right orientation of the desired inserted fragments of Core and E2 were
conﬁrmed via sequencing prior to expression and were then transformed in BL21 (DE3) pLysS strains of
E. coli and induced with 0.5 mM Isopropyl-b-D-thiogalactopyranoside (IPTG) for the production of
antigenic recombinant proteins. The produced truncated antigens were then puriﬁed by Nickel afﬁnity
chromatography and were conﬁrmed by western blotting, immunoblotting and enzyme-linked
immunosorbent assay (ELISA).
Results: The expressed Core and E2 recombinant antigens were used to develop immunoblotting assay
for the detection of anti-HCV antibodies in sera. With immunoblotting, a total of 93-HCV infected sera
and 35-HCV negative individuals were tested for the presence of anti-HCV antibodies to the Core and E2
antigens. Recombinant antigen showed 100% reactivity against HCV infected sera, with no cross
reactivity against HCV-negative sera. The immunoblot assay mixture of recombinant antigens (Core+E2)
showed a strong reaction intensity in the test area (TA) as compared to the individual truncated Core and
E2 recombinant antigens. In the in-house ELISA assay, mixed Core and E2 recombinant antigens showed
100% reactivity against a standardized panel of 150-HCV-positive sera and non reactivity against a
standardized panel of 150 HCV-negative sera while also being non reactive to sera positive for other viral
infections. The antigenic recombinant antigens also were tested for the 30 sera of known genotypes. The
antigens did not detect antibodies to genotype-3a, but detected antibodies to all genotypes and did not
discriminate them genotype wise. A panel of 175 of HCV-suspected serum samples was subjected to
comparative analysis with our in-house ELISA assay and with commercial HCV screening assays. After
subjecting the results to the formulas for determining the quality parameters, immunoblot assay had
100% sensitivity and speciﬁcity, while the ELISA assay had 100% sensitivity and 98.8% speciﬁcity as
compared to commercially available assays.
Conclusion: This study indicates that a mixture of Core and E2 antigens are potentially valuable antigens
and there is the possibility of developing serological assays for monitoring HCV infection.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Table 1
Primer sequences used for the ampliﬁcation of full length Core and E2 genes
Primer Name Sequence Ampliﬁed gene
product size
Core-F 50-ATGAGCACACTTCCTAAACCTCA-30 573-bp
Core-R 50-TGGCTGCTGGATGAATTAAGC-30
E2-F 50-CACACATATACCACCGGTGG -30 1056-bp
E2-R 50-CGTCCGCCAGAAGGAGGA -30
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Hepatitis C virus (HCV) may be called a silent killer virus
because most HCV infected people are unaware of the HCV
presence in their bodies, even decade after infection. Globally more
than 170 million subjects are infected with HCV, often via contact
with contaminated blood.1 HCV is small single stranded RNA (+)
virus classiﬁed in the genus Hepacivirus within the Flaviridae
family.2,3 Amongst HCV proteins, Core antigen, besides its
signiﬁcance for diagnostic application, is an important target in
the efforts to develop preventive and therapeutic strategies against
this pathogen.4 HCV Core antigen is highly antigenic, induces
cellular and humoral speciﬁc responses and most probably plays a
key role in the pathogenesis of HCV viral infection.5 Several studies
conﬁrm that one of the main components of routine kits for recent
detection of HCV infection is Core antigen.6,7
The ﬁrst identiﬁed conformational protein was the envelope E2
antigen, which might have played an important role in immuno-
reactivity in HCV-infected patients.8 E2 antigen is considered a
prime candidate for anti-HCV vaccine.9 In one study anti-E2
antibodies were seen in >90% of HCV RNA positive individuals
using E2 antigen,10 and the E2 protein might be useful for
monitoring of HCV infection.11
Several efforts have been made to develop efﬁcient serological
tests for the screening of HCV infection.12 The ELISA assay or
immunoblot assays uses HCV recombinant viral antigens corre-
sponding to multiple polypeptides from various viral fragments,
including structural proteins and non-structural proteins.13 These
serological screening assays combine improved sensitivity and
speciﬁcity, however still fail to diagnose HCV infection more
accurately.14
Countrywide, no serological screening tests are available for
HCV, and only imported kits are used for the diagnosis of HCV.
However these imported kits are unable to screen the local
population for HCV infection accurately.15 Moreover, Pakistan is a
developing country and there is a ﬁnancial burden associated with
importing the HCV screening kits. Therefore, the purpose of our
study was to develop highly sensitive, inexpensive and simple
serological assays for the screening of HCV infection utilizing a
mixture of recombinant (Core & E2) antigens to detect the presence
of HCV antibodies in serum specimens. To the best of our
knowledge this is the ﬁrst report from Pakistan in which the
mixture of Core and E2 antigens of HCV-3a was used for the in-
house screening of HCV infection.
2. Methodology
2.1. Ampliﬁcation and sequencing of Core and E2 genes of HCV-3a
Chronically HCV infected serum samples with genotype-3a
were kindly provided by the Division of Molecular Virology and
Molecular Diagnostics, National Centre of Excellence in Molecular
Biology (CEMB), Lahore, Pakistan. The HCV RNA was isolated from
genotype-3a using a RNA extraction kit (Gentra, life technologies,
USA) according to kit protocol. The viral RNA was reverse
transcribed to cDNA using 100 U of M-MLV RTEs at temperatureTable 2
Primer sequences used for ampliﬁcation of antigenic sites of Core and E2 genes
Primer Name Sequences 
Core-F 50- AAGCTTGCCACCATGAGCACACTTCCTAAACCT -30
Core-R 50- CTCGAGGTCATTTGGG CCC CAGGATGG -30
E2-F 50- AAGCTTGCCACCATGACGTGCGGAGCT CCCCCCTGT
E2-R 50- CTCGAGATGCAGCAGCGGATGTTG -30
The underlined sequences represented the restriction sites of HindIII and XhoIof 37 8C for 50 min. cDNA was utilized as a template for the
ampliﬁcation of full length core and E2 genes using gene speciﬁc
primers (Table 1). Primers were designed using Primer3 software
by GU294484.1 as a reference sequence. Ampliﬁed products of
Core and E2 genes were sequenced using an automated gene
sequencer (Applied Biosystems), and sequences of the Core
(accession number KC796013) and E2 (accession number-
KC796015) genes were submitted to the gene bank.
2.2. Selection and ampliﬁcation of antigenic sites of Core and E2 genes
Antigenic sites (truncated regions) were selected within
the Core and E2 genes of HCV-3a using software (http://
www.bioinformatics.org/JaMBW/3/1/7/). The antigenic nucleotide
sequences of Core (nt-336) and E2 (nt-342) genes were ampliﬁed
using forward primers containing HindIII restriction sites, while
the reverse primers contained XhoI restriction site (Table 2).
2.3. Construction of expression plasmids and bacterial transformation
The ampliﬁed products of truncated Core and truncated E2
were treated with HindIII and XhoI restriction enzymes and pET-
28a vector as well. The digested Core and E2 products were cloned
into digested pET-28a vector to construct the expression plasmids.
The pET-28a vectors horbouring the truncated Core insert and
truncated E2 insert were digested with restriction enzymes
(HindIII & XhoI). The right orientation of the desired fragments
was conﬁrmed by DNA sequencing. Transformation was carried
out using competent BL21 DE3 pLysS), bacterial cells and 1 ml of
isolated plasmid of pET-28a horbouring antigenic Core and E2, and
then heat shocking for 90 second at 428C. LB medium of 500 ml free
of antibiotics was added and incubated for 1 h at 378C.
Subsequently about 150 ml transformants of truncated Core and
E2 was spread on LB-agar plates containing kanamycin (25 mg/ml)
and chloramphenicol (25 mg/ml) and incubated overnight (O/N).
2.4. Expression and puriﬁcation of Core and E2 antigens
BL21 (DE3) pLysS transformed colonies were picked using a
sterile loop, immersed into a tube containing kanamycin (25 mg/
ml) and chloramphenicol (25 mg/ml) antibiotic LB media, and then
incubated O/N at 378C for 200 rpm. The O/N culture was further
diluted with 1:50 dilution in sterile LB medium containing
antibiotics, and the inoculums were allowed to grow in autoclaved
1L ﬂasks, incubated for 250 rpm at 378C to attain the opticalRestriction site Ampliﬁed product size
HindIII 336-bp
XhoI
 -30 HindIII 342-bp
XhoI
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3 h at 378C for the maximum production of truncated Core and E2
antigens. The IPTG induced culture was then centrifuged (Beckman
USA) at 600 rpm for 15 min at 408C. The pellet was re-suspended in
1X PBS, sonicated (Mixsonic USA) four times in an ice bath for
30 seconds with 4 pulses, and centrifuged at 13,000 rpm for 15 min
at 48C, and then the supernatant was shifted into a fresh tube.
Recombinant proteins were then puriﬁed with Ni-NTA column
containing Ni2+-nitriloacetate agarose resin (Invetrogen, USA).
Protein supernatants was poured into the column and allowed to
run. After the sample was completely poured into column, the
column was washed with washing buffer (1X PBS and 40 mM
imidazole, pH 8). The conjugated His-Core and His-E2 truncated
proteins were then eluted from the column by adding elution
buffer (1X PBS and 250 mM imidazole, pH 8). The puriﬁed protein
was quantiﬁed using Bradford assay (Bio-rad, USA).
2.5. SDS-PAGE and western blot analysis of recombinant antigens
The recombinant truncated Core and E2 proteins were
electrophoretically separated on 12% SDS-PAGE and dyed with
Coomassie blue. For western blotting analysis the protein was
transferred from gel and then shifted to nitrocellulose membrane
using a semi-dry blotting apparatus (Biorad, USA) for 90 min at
16 V. The membranes were blocked with 5% blocking buffer for
1:30 h at room temperature (RT) and washed with PBST and then
incubated with mouse anti-His6 monoclonal antibodies at 48C O/N.
The membranes were washed and then incubated with Alkaline
Posphatase (AP) conjugated anti-mouse secondary antibody IgG
diluted for 1 h at RT followed by washes with PBST, and then the
membrane was treated with NBT/BCIP substrate for 15 min at
37 8C. The membrane was dried and then photographed.
2.6. Detection of anti-HCV antibodies in human sera by
immunoblotting
The nitrocellulose membrane was cut into strips, and we
applied 1.6 ml of truncated Core and E2 recombinant antigens at
concentrations of 24 mg/ml and 28 mg/ml in the test area (TA),
respectively. Subsequently, 1.6 ml of the truncated Core & E2
antigens and a mixture with same concentrations was applied in
the TA and 1.5 ml of extracellular recombinant protein A (Sigma
USA) at the concentration of 6 mg/ml was applied in the control
area (CA) and allowed to dry for 1 h at RT and then was blocked for
1 h at RT using blocking buffer. The strips were washed two times
with PBST and then incubated for 2 h with HCV infected sera
diluted 1:50 in PBST at 48C. Strips were washed and then incubated
for 1 h with horseradish peroxidase (HRP) conjugated rabbit anti-
human IgG antibodies diluted 1/1000 in PBST and washed with
PBST again. For the recognition of the bound anti-human IgG-HRP,
4-chloro-1-naphthol and H2O2 solution was utilized as a substrate.
The strips were then dried and photographed. A similar procedure
was followed for the HCV negative sera.
2.7. Detection of antibodies to HCV in serum samples by ELISA
The immunoreactivity of the mixture of Core and E2 recombi-
nant proteins with antibodies circulating in the HCV positive sera
was observed with microtiter immune plates coated with 100 ml of
the mixed (Core & E2) antigens, at 0.3 mg/ml concentration per
well. The mixture of (Core+E2) antigens was adsorbed on to the
micro ELISA plates for O/N at 48C. Wells were blocked following
washing with PBST. We then added 100 ml (diluted 1/50) of serum
samples positive & negative for HCV and for other viral diseases, i.e.
HBV, HEV and dengue virus, to each well of the plate and then
incubated the plate at 378C for 1:30 h. In brief 100 ml of themixture (Core+E2) of recombinant antigens was added to each well
of the plate and incubated O/N at 48C. The wells were blocked with
blocking buffer and then washed with PBST. After this, 100 ml of
each serum sample of HCV known genotypes (1a, 1b, 2a, 3a & 3b)
was added per well of the plate and incubated at 378C for 1:30 h.
The plates were washed and then incubated with 100 ml rabbit
anti-human IgG conjugated to HRP at 378C for 30 min. The ultimate
immune complexes were seen by adding 100 ml TMB substrate
solution, the wells were blocked, and then the absorbance at
450 nm of each well was read using an ELISA reader (Bioteck, USA).
To distinguish between positive and negative HCV sera the cutoff
value was calculated as the mean value of the OD of HCV
150 negative samples plus 2 Standard Deviations (SD) equal to
0.09. According on this calculated cut-off value the ﬁndings of anti-
HCV screening assay were calculated as described earlier.16
2.8. Data analysis
The calculations of sensitivity, speciﬁcity, positive predictive,
and negative predictive values were carried out by applying the
formulas.17 Receiver operating curves (ROC) were generated; area
under the curve (AUC) and its standard errors & 95% conﬁdence
intervals were calculated using SPSS-17 version.
3. Results
3.1. PCR ampliﬁcation and restriction digestion of full and truncated
Core and E2 genes
Full length and antigenic (truncated) Core and E2 genes of HCV-
3a were ampliﬁed using each gene speciﬁc primer as described in
methods and materials. The ampliﬁed gene products of full and
truncated genes were conﬁrmed by restriction digestion and
sequencing.
3.2. Expression, western blotting and puriﬁcation of Core & E2
antigens
Total cell lysates induced and uninduced from Bl21 (DE3) plysS
were separated on a 12% SDS-PAGE and the expected sizes of
truncated Core (12.3-kDa) and truncated E2 (12.5-kDa) antigens
were seen. The puriﬁed proteins were checked using SDS
polyacrylamide stained with silver staining to demonstrate the
purity of puriﬁed antigens. The quantity of Core antigen was
1.5 mg and of E2 antigen was 2.2 mg respectively after puriﬁcation.
The antigenic recombinant proteins were further conﬁrmed by
western blotting for the identiﬁcation of antigenic (Core & E2)
recombinant products.
3.3. Immunoblot analysis of Core and E2 recombinant antigens
The immunobloting assay was carried out for 128 serum
samples, out of which 93 serum samples were conﬁrmed positive
for anti-HCV and RNA PCR and 35 samples were HCV negative. The
1.6 ml of truncated recombinant Core at a concentration of 24 mg/
ml and E2 at a concentration of 28 mg/ml and a mixture of the
truncated recombinant proteins (Core+E2) of the same concentra-
tions were applied in test area (TA). The 1.5 ml of recombinant A at
a concentration of 6 mg/ml was applied in control area (CA). There
was no reaction in the CA area, only a mark in the control area was
seen while treating with negative serum samples. The results of
developed immunoblot tests and applying the results to formulas
for determining the sensitivity, speciﬁcity, positive and negative
predictive values were 100%. Immunoblotting tests can be seen in
Fig. 1.
Figure 1. Detection of anti-Core, and anti-E2 antibodies in human sera by immunoblot analysis using the Core, E2 and mixture (Core & E2) of antigenic recombinant proteins
at concentration of 24 mg/ml, and 28 mg/ml respectively. Nitrocellulose sheets, cut into strips and reacted with human sera. Strips 1-93 HCV-positive sera; row 1: Core antigen
in test area (TA), 2: E2 antigen in TA, 3: mixture of Core & E2 antigens, 4: extracellular recombinant protein A (Sigma) in control area (CA) at a concentration of 6 mg/ml. Strips
94-128 HCV negative control serum only a mark was seen in CA.
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mixture of Core & E2 antigens
We evaluated the immunoreactivity of the mixture of Core and
E2 antigenic recombinant proteins in the ELISA assay. For the
validation of the ELISA assay a standardized panel was established
by the Division of virology CEMB, and 150-HCV positive sera and
150-HCV sera were screened in the ELISA using the mixed
recombinant antigens. All of the 150-HCV positive sera presented
values above the cut-off value (0.09) and all of the 150 HCV
negative sera presented values below the cut-off value. The 30 sera
of known genotypes (5 with genotype-1a, 4 with genotype-1b,
4 with genotype-2a, 11 with genotype-3a, & 6 with genotype-3b)
were received from CEMB diagnostic lab to conﬁrm the antigen
reactivity against infected sera of selected genotypes. All of the
selected genotype sera presented values above the cut off value
and showed reactivity regardless of genotype speciﬁcity. Further-
more patient sera positive for other viral infections including 7 sera
positive for HBV, 7 sera positive for HEV and 7 sera positive for
dengue virus were also tested, and presented values below the cut-
off value (Fig. 2).
3.5. Validation of developed in house ELISA assay via HCV suspected
sera
For the validation of ELISA analysis, 175 sera from patients
suspected of HCV were randomly selected from almost all regions
of Pakistan. Comparative analysis of suspected sera by the presentstudy using four assays is summarized in Table 3. Out of a total
175 sera, 85 sera were positive by our diagnostic ELISA assays and
PCR assays, and were used as a reference standard while one serum
out of 85 was observed negative by the commercial anti-HCV Ag
assay and two sera out of 85 positive sera were found negative by
another commercial HCV CORE Ag assay, respectively. The
remaining 90 sera were found negative for HCV by PCR assay,
while in 90 of these negative samples, our assay conﬁrmed 89 as
negative and gave one false positive result, whereas commercial
anti-HCV Ag and Core Ag assays gave 2 and 4 false positive results.
It is conﬁrmed that the in-house anti-HCV ELISA diagnostic assay is
high sensitivity (100%) and speciﬁcity (98.8%) and is valuable for
the diagnosis of anti-HCV antibodies in infected-sera, while the
sensitivities and speciﬁcities of commercial CORE Ag and anti-HCV
Ag assays were 97.6%, 98.8%, 95.5% & 97.7%, respectively in
comparative analyses. The use of the mixture (Core+E2) of
antigenic recombinant proteins is a novel method in the ELISA
diagnostic method; countrywide the mixture of antigenic peptides
(core+E2) were used for the ﬁrst time for the screening of HCV
infection and have shown high sensitivity and speciﬁcity as
compared to commercial assays. The sensitivities, speciﬁcities,
positive predictive values (PPV) and negative predictive values
(NPV) of the in-house ELISA assay and commercial assays are
shown in Table 4. The receiving operating curves (ROC) demon-
strate the association between the true positive ratio (sensitivity)
and false positive ratio (1-speciﬁcity). In the present study we used
ROC to distinguish sensitivity and speciﬁcity for the in-house ELISA
assay and commercial assays (Fig. 3) and to compare the areas
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Figure 2. Diagrammatic representations of the OD 450 nm values obtained from the mixture of (Core+E2) antigenic recombinant proteins. ELISA-based test for the detection
of the anti-Core, and anti-E2 antibodies in human sera samples. 1-7: HBV-positive sera, 8-14: HEV-positive sera, 15-21: Dengue virus-positive sera, 22-42 HCV infected sera of
known genotypes (1a, 1b, 2a 3a & 3b,). 42-271: HCV-positive sera and 272-341 HCV-negative sera.
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commercial assays. Areas under the curve and its Standard errors
(SEs) & 95% conﬁdence intervals are summarized in Table 5.
4. Discussion
The serological diagnosis of hepatitis C virus infection has been
based on the identiﬁcation of anti-HCV speciﬁc antibodies since
1989, when HCV was ﬁrst cloned,2,3 and many immunoassays for
the identiﬁcation of anti-HCV antibodies in infected sera have been
used.12 In this report we mapped the antigenic sites in Core and E2
genes of HCV-3a and cloned in pET-28a expression vector for the
production of truncated Core and E2 recombinant antigens, which
were then studied for their potential assessment as diagnostic
antigens for the identiﬁcation of anti-HCV antibodies in HCV
infected sera. The production of truncated recombinant Core and
E2 antigens was conﬁrmed by western blotting, and their
serological reactivity was examined by immunoblotting and ELISA.Table 3
Comparative analyses of in-house ELISA assay, commercially available ELISA
assays,and HCV RNA PCR as reference standard
Patient sera Mixed
antigensa
Anti-HCVAgb HCV
CORE Agc
PCR reference
standardd
HCV true positive 85 84 83 85
HCV true negative 89 88 86 90
HCV false-positive 1 2 4 0
HCV false-negative 0 1 2 0
Total 175 175 175 175
a Mixed antigens (C+E2) of HCV-3a were used in our in-house ELISA assay
b The commercial anti-HCV kit was used for comparative analysis
c The commercial HCV CORE antigen kit was used for comparative analysis
d The HCV RNA PCR was used as a reference standard in the comparison
Table 4
Parameters for the in-house ELISA diagnostic method and commercial ELISA assays
Diagnostic
Assays
Sensitivity Speciﬁcity Positive
Predictive
values
Negative
Predictive
values
In-house ELISA
assay
100% 98.8% 98.8% 100%
Anti-HCV Ag 98.8% 97.7% 97.67% 98.8%
HCV CORE Ag 97.6% 95.5% 97.64% 97.72%Our truncated Core and E2 recombinant antigens were reactive
against the HCV-positive sera, and non-reactive against HCV
negative sera.
Several studies have indicated that a truncated Core protein is a
major antigenic component in diagnostic ELISA kits and shows
better reactivity,18 while other studies demonstrated that the full-
length Core protein has better reactivity than truncated Core
protein.19 However our expressed truncated Core antigen showed
strong reactivity in 100% of PCR-positive samples and can act as a
potential diagnosis tool for HCV infection. These results are
markedly similar with the previous study in which the expressed
HCV Core antigen showed 100% reactivity of PCR positive sera.15
In one study the percentage of sera of HCV infected patients that
reacted with E2 antigen was about 70%,11 which is lower than
another previously published report that 90% of chronically HCV
infected patients reacted with E2 protein.10 Our antigenic E2Figure 3. Receiver operation curve (ROC) distinguish sensitivity and speciﬁcity of
in-house ELISA and commercial ELSA assays.
Table 5
Test results variables of in-house ELISA and commercial ELISA assays
Diagnostic Assays AUC Std. Errors 95% conﬁdence intervals
In-house ELISA 0.994 0.006 0.982-1.007
Anti-HCV Ag 0.983 0.011 0.961-1.005
HCV CORE Ag 0.966 0.16 0.935-0.997
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positive samples and might have a potential for the screening of
HCV infection.
Considering the above potential and the diagnostic value of
Core and E2 antigens, we used a mixture of both recombinant
antigens (Core & E2) in immunoblot and ELISA diagnostic assays to
achieve the maximum sensitivity and speciﬁcity for monitoring
HCV infection. To accomplish the highest possible sensitivity and
speciﬁcity for the serological screening of HCV, we used the
mixture (Core+E2) of recombinant antigens in immunoblot assay.
In the immunoblotting there was the highest reaction intensity in
the test area (TA) when the mixture of Core and E2 antigens were
used collectively, as compared with the individual Core and E2
proteins. Notably, these results are in agreement with recently
developed immunoblot assay.17
In the CA of the immunoblotting assay we used the extracellular
recombinant protein A, which has been used for some time to
develop immunochromatographic tests, together with particle
capture conjugated to colloidal gold as the line capturing test for
antibodies in sera.20 The sensitivity and speciﬁcity of the
immunoblot assay were 100%, so these results veriﬁed that there
is the possibility to construct an economical clinical in-house
immunochromatographic test for the detection of anti-HCV
antibodies using mixture of recombinant Core and E2 antigens.
The ELISA assays was designed with the results achieved in the
assessment of the immunoblot assay, so we used only the mixed
antigens (Core+E2) in ELISA analysis. In an ELISA assay the mixed
(Core+E2) antigens showed 100% reactivity against HCV infected
sera, they did not show any cross-reactivity in the presence of HCV-
negative sera with exception of one patient who showed reactivity
for an unknown reason, and further did not show any reactivity
against serum samples positive for other viral infections (HBV, HEV
& Dengue virus). Mixed antigens also showed 100% reactivity
against the sera of HCV known genotypes regardless of genotype
speciﬁcity, and thus ruled out the use of these antigenic peptides
for establishing an immunoassay for HCV speciﬁc genotypes.
However, several published reports also rule out the genotype-
speciﬁc nature of expressed recombinant antigens.21 The sensitiv-
ity and speciﬁcity of our developed in-house ELISA assay was 100%
and 98.8% respectively as compared to the commercials assays,
which speciﬁcity is higher than the speciﬁcity (87.5%) of a recently
developed ELISA assay using truncated Core and E2 recombinant
antigens.17 Thus there is also a possibility to develop a local ELISA
assay for the screening of HCV. Our developed serological methods
for HCV screening are more suitable for circumstances in Pakistan,
to reduce the import of HCV diagnostic kits and to be optimized
more accurately for the screening of local HCV strains
5. Conclusion
Based on our results the mixture of antigenic recombinant
proteins (Core+E2) used in immunoblotting and ELISA assays
showed maximum sensitivity and speciﬁcity. Thus the expressed
proteins were potentially valuable antigens for developing a
clinical immunochromatographic test and ELISA diagnostic meth-
od for in-house screening of HCV-infection.
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